Intraocular injectable hydrogels for the delivery of cells and nanoparticles
Source abstract
Abstract
The rising global life expectancy has led to a growing prevalence of ophthalmic diseases, while current treatments face important limitations in terms of efficacy, costs, and patient compliance. The use of injectable hydrogels as drug and cell carriers is a promising approach, compared to the injection of drug solutions or cell suspensions. This is because the hydrogel matrix may offer protection against clearance or degradation, may modulate drug/cell release, and provide a biomimetic substrate for differentiating cells while being minimally invasive. On one hand, injectable hydrogels for ocular drug delivery have been traditionally designed to host and release small drugs or proteins. However, limitations such as high burst release and difficulty of entrapping hydrophobic molecules led to the emergence of nanocomposite hydrogels, where the drug is entrapped in nanoparticles prior hydrogel incorporation. Composite systems offer great advantages over the injection of particle suspensions, improving particle fate and drug release kinetics. On the other hand, injectable hydrogels offer a cell-friendly environment to seek tissue regeneration, providing biomechanical and biochemical cues for cellular cross-talk, differentiation, and formation of new extracellular matrix. This review critically discusses recent advancements in the development of novel injectable hydrogels as delivery vehicles for drug-loaded nanoparticles and cells, with a major focus on the formulation components, administration routes, and other factors affecting performance, highlighting promising aspects and challenges to address in the future.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Corneal Surgery and Treatments · Ocular Surface and Contact Lens · Retinal Development and Disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. The lancet global Health commission on global eye Health: vision beyond 202010.1016/S2214-109X(20)30488-5 ↗
2. Assessing the economic burden of vision loss and irreversible legal blindness in Spain (2021–2030): a societal perspective10.1186/s13561-024-00546-y ↗
3. World report on vision
4. Eye surgery in the elderly10.2147/CIA.S101835 ↗
5. Biotechnology and biomaterial-based therapeutic strategies for age-related macular degeneration. Part II: cell and tissue engineering therapies
6. Subretinal implantation of retinal pigment epithelial cells derived from human embryonic stem cells: improved survival when implanted as a monolayer10.1167/iovs.12-11239 ↗
7. A novel approach for subretinal implantation of ultrathin substrates containing stem cell-derived retinal pigment epithelium monolayer10.1159/000338749 ↗
8. Cell–matrix interactions in the eye: from cornea to choroid10.3390/cells10030687 ↗
9. Transplantation of human embryonic stem cell-derived retinal tissue in two primate models of retinal degeneration10.1073/pnas.1512590113 ↗
10. Establishment of immunodeficient retinal degeneration model mice and functional maturation of human ESC-derived retinal sheets after transplantation10.1016/j.stemcr.2018.01.032 ↗
11. iPSC-derived retina transplants improve vision in rd1 end-stage retinal-degeneration mice10.1016/j.stemcr.2016.12.008 ↗
12. Sustained release of nitric oxide and cascade generation of reactive nitrogen/oxygen species via an injectable hydrogel for tumor synergistic therapy
13. An injectable and active hydrogel induces mutually enhanced mild magnetic hyperthermia and ferroptosis
14. PEG-based thermosensitive and biodegradable hydrogels10.1016/j.actbio.2021.04.009 ↗
15. Autophagy inhibition mediated via an injectable and NO-releasing hydrogel for amplifying the antitumor efficacy of mild magnetic hyperthermia
16. Versatile hypoxic extracellular vesicles laden in an injectable and bioactive hydrogel for accelerated bone regeneration
17. Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery10.1039/C7TB01556A ↗
18. Sustained intravitreal delivery of dexamethasone using an injectable and biodegradable thermogel10.1016/j.actbio.2015.05.005 ↗
19. Composite nanoformulation therapeutics for long-term ocular delivery of macromolecules10.1021/acs.molpharmaceut.5b00828 ↗
20. Simultaneous release of aflibercept and dexamethasone from an ocular drug delivery system10.1080/02713683.2022.2053166 ↗
21. A hyaluronan-based injectable hydrogel improves the survival and integration of stem cell progeny following transplantation10.1016/j.stemcr.2015.04.008 ↗
22. Thiolated hyaluronan-based hydrogels crosslinked using oxidized glutathione: an injectable matrix designed for ophthalmic applications10.1016/j.actbio.2013.09.029 ↗
23. Mussel-inspired injectable hydrogel and its counterpart for actuating proliferation and neuronal differentiation of retinal progenitor cells10.1016/j.biomaterials.2018.12.015 ↗
24. The application of hyaluronic acid hydrogels to retinal progenitor cell transplantation10.1089/ten.tea.2012.0209 ↗
25. Nanocomposites: a brief review10.1007/s12553-019-00380-x ↗
26. Nanocomposite hydrogels for biomedical applications10.1002/btm2.10315 ↗
27. Advances in ocular drug delivery systems10.1038/s41433-020-0809-0 ↗
28. Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy
29. Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions10.1038/s41392-024-01852-x ↗
30. Injectable hydrogels for ophthalmic applications10.1016/j.jconrel.2017.10.031 ↗
31. Recent advances in hydrogels: ophthalmic applications in cell delivery, vitreous substitutes, and ocular adhesives10.3390/biomedicines9091203 ↗
32. Injectable hydrogels based on biopolymers for the treatment of ocular diseases
33. GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision
34. Encapsulated cells for long-term secretion of soluble VEGF receptor 1: material optimization and simulation of ocular drug response10.1016/j.ejpb.2014.10.005 ↗
35. Both non-coated and polyelectrolytically-coated intraocular collagen-alginate composite gels enhanced photoreceptor survival in retinal degeneration
36. Hydrogels-based ophthalmic drug delivery systems for treatment of ocular diseases
37. Intravitreal hydrogels for sustained release of therapeutic proteins10.1016/j.jconrel.2020.07.031 ↗
38. Hydrogel-based ocular drug delivery systems: emerging fabrication strategies, applications, and bench-to-bedside manufacturing considerations10.1016/j.jconrel.2019.05.034 ↗
39. Inherited Retinal Dystrophies: the role of gene expression regulators10.1016/j.biocel.2015.02.007 ↗
40. Controlled ocular drug delivery with nanomicelles10.1002/wnan.1272 ↗
41. Ocular autonomic nervous system: an update from anatomy to physiological functions
42. Is the conjunctiva a potential target for advanced therapy medicinal products?10.3390/pharmaceutics13081140 ↗
43. Ciliary body and ciliary epithelium nicholas
44. Hejtmancik · 2015 · vol. 134
45. Current methods and new approaches to assess aqueous humor dynamics10.1080/17469899.2021.1902308 ↗
46. Adult vitreous structure and postnatal changes10.1038/eye.2008.21 ↗
47. Scleral structure and biomechanics
48. Sustained-release corticosteroid expands armamentarium for uveitis
49. Detection of macula and fovea for disease analysis in color fundus images
50. Retinal bipolar cells: elementary building blocks of vision10.1038/nrn3783 ↗
51. Retinal horizontal cells: challenging paradigms of neural development and cancer biology10.1242/dev.033175 ↗
52. Human ocular anatomy10.1016/j.clindermatol.2014.10.006 ↗
53. Nanotherapy for posterior eye diseases10.1016/j.jconrel.2014.05.031 ↗
54. Novel approaches to retinal drug delivery10.1517/17425247.4.4.371 ↗
55. The number of people with glaucoma worldwide in 2010 and 202010.1136/bjo.2005.081224 ↗
56. Outcomes of glaucoma referrals in adults aged 18 to 40 years10.1001/jamanetworkopen.2024.57843 ↗
57. The pathophysiology and treatment of glaucoma: a review10.1001/jama.2014.3192 ↗
58. Glaucoma treatment trends: a review10.1016/j.jcjo.2016.07.013 ↗
59. Novel therapies for the prevention of fibrosis in glaucoma filtration surgery10.3390/biomedicines11030657 ↗
60. Chitosan-based nanostructures: a delivery platform for ocular therapeutics10.1016/j.addr.2009.11.026 ↗
61. Genes and mutations causing retinitis pigmentosa10.1111/cge.12203 ↗
62. Retinitis pigmentosa and stem cell therapy10.18240/ijo.2024.07.22 ↗
63. Long-Term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients10.1186/s13287-017-0661-8 ↗
64. Stem cell transplantation as a progressing treatment for retinitis pigmentosa10.1007/s00441-021-03551-3 ↗
65. Review and update: current treatment trends for patients with retinitis pigmentosa10.1016/j.optm.2008.01.026 ↗
66. Injectable hydrogels for central nervous system therapy10.1088/1748-6041/7/2/024101 ↗
67. Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective10.1016/j.survophthal.2012.01.004 ↗
68. Angiogenic growth factors and their inhibitors in diabetic retinopathy10.2174/157339910793360815 ↗
69. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies10.1172/jci.insight.93751 ↗
70. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study10.1016/S0161-6420(03)00579-7 ↗
71. Cell-adhesive thermogelling PNIPAAm/hyaluronic acid cell delivery hydrogels for potential application as minimally invasive retinal therapeutics10.1002/jbm.a.34021 ↗
72. Age related macular degeneration10.1136/bmj.326.7387.485 ↗
73. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis10.1136/bjophthalmol-2014-305149 ↗
74. Enhanced proliferation and differentiation of retinal progenitor cells through a self-healing injectable hydrogel10.1039/C8BM01579A ↗
75. Injectable composite hydrogels encapsulating gelatin methacryloyl/chitosan microspheres as ARPE-19 cell transplantation carriers10.1039/D2BM01413K ↗
76. Synthesis and biomedical applications of self-healing hydrogels
77. Recent advances in shear-thinning and self-healing hydrogels for biomedical applications10.1002/app.48668 ↗
78. Hydrogel-based drug delivery systems: comparison of drug diffusivity and release kinetics10.1016/j.jconrel.2009.10.030 ↗
79. Evolution of biomaterials
80. Current and future prospective of injectable hydrogels—design challenges and limitations10.3390/ph15030371 ↗
81. Advances in biodegradable and injectable hydrogels for biomedical applications10.1016/j.jconrel.2020.12.008 ↗
82. Injectable hydrogels of newly designed brush biopolymers as sustained drug-delivery vehicle for melanoma treatment10.1038/s41392-020-00431-0 ↗
83. Self-healing polysaccharide-based hydrogels as injectable carriers for neural stem cells10.1038/srep37841 ↗
84. A hydrogel-based stem cell delivery system to treat retinal degenerative diseases10.1016/j.biomaterials.2009.12.004 ↗
85. Injectable, antioxidative, and tissue-adhesive nanocomposite hydrogel as a potential treatment for inner retina injuries10.1002/advs.202308635 ↗
86. Development of self-healing hydrogels to support choroidal endothelial cell transplantation for the treatment of early age related macular degeneration
87. Fabrication and evaluation of gellan gum/hyaluronic acid hydrogel for retinal tissue engineering biomaterial and the influence of substrate stress relaxation on retinal pigment epithelial cells10.3390/molecules27175512 ↗
88. Corneal repair by human corneal keratocyte-reprogrammed iPSCs and amphiphatic carboxymethyl-hexanoyl chitosan hydrogel10.1016/j.biomaterials.2012.07.029 ↗
89. A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy10.1038/s41536-021-00195-3 ↗
90. Single subcutaneous injection of the minocycline nanocomposite-loaded thermosensitive hydrogel for the effective attenuation of experimental autoimmune uveitis
91. Hyaluronic acid-based nanocomposite hydrogels for ocular drug delivery applications10.1002/jbm.a.34976 ↗
92. In vivo efficacy of an injectable microsphere-hydrogel ocular drug delivery system10.1080/02713683.2017.1302590 ↗
93. Preparation, physicochemical, and retinal anti-angiogenic evaluation of poloxamer hydrogel containing dexamethasone/avastin-loaded chitosan-N-acetyl-L-cysteine nanoparticles10.1016/j.ijbiomac.2022.09.101 ↗
94. Optimization of an injectable hydrogel depot system for the controlled release of retinal-targeted hybrid nanoparticles
95. A long-acting curcumin nanoparticle/in situ hydrogel composite for the treatment of uveal melanoma10.3390/pharmaceutics13091335 ↗
96. A novel, liposome-loaded, injectable hydrogel for enhanced treatment of choroidal neovascularization by sub-tenon’s injection
97. An injectable nano-enabled thermogel to attain controlled delivery of p11 peptide for the potential treatment of ocular angiogenic disorders of the posterior segment10.3390/pharmaceutics13020176 ↗
98. Rapid bioprinting of conjunctival stem cell micro-constructs for subconjunctival ocular injection
99. Recent advances in injectable hydrogels for controlled and local drug delivery10.1002/adhm.202001341 ↗
100. Mesenchymal stem cell-laden in situ-forming hydrogel for preventing corneal stromal opacity10.1097/ICO.0000000000003475 ↗